Humabs BioMed SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Humabs BioMed SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11183
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:16
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Humabs BioMed SA (Humabs), a subsidiary of Vir Biotechnology Inc, is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company’s pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develops cellclone technologies, a proprietary platform that delivers a pipeline of human monoclonal antibodies, and demonstrates the antibodies effectiveness in both in-vivo and in-vitro. Humabs technology platform uses immortalized B cells or cultured plasma cells obtained from the blood or lymphoid organs of the donor. The company’s pipeline products are used in the treatment of cancer, inflammatory and infectious diseases. It partners with pharmaceutical companies, government agencies, academic institution, and universities. Humabs is headquartered in Bellinzona, Switzerland.

Humabs BioMed SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humabs BioMed SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Agilvax Enters into Development Agreement with Humabs Biomed 10
Licensing Agreements 11
Humabs Biomed Enters into Licensing Agreement with MedImmune 11
Acquisition 12
Vir Biotechnology Acquires Humabs BioMed 12
Humabs BioMed SA – Key Competitors 13
Humabs BioMed SA – Key Employees 14
Humabs BioMed SA – Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
About GlobalData 16
Contact Us 16
Disclaimer 16

List of Tables
Humabs BioMed SA, Pharmaceuticals & Healthcare, Key Facts 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humabs BioMed SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humabs BioMed SA, Deals By Therapy Area, 2012 to YTD 2018 8
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Agilvax Enters into Development Agreement with Humabs Biomed 10
Humabs Biomed Enters into Licensing Agreement with MedImmune 11
Vir Biotechnology Acquires Humabs BioMed 12
Humabs BioMed SA, Key Competitors 13
Humabs BioMed SA, Key Employees 14

List of Figures
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Humabs BioMed SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Humabs BioMed SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Duke Energy Corporation:企業の戦略・SWOT・財務情報
    Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Energy Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • New World Development Co Ltd (17):企業の財務・戦略的SWOT分析
    New World Development Co Ltd (17) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Sunquest Information Systems Inc:企業の戦略的SWOT分析
    Sunquest Information Systems Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Harrison Catering Services Ltd.:企業の戦略・SWOT・財務情報
    Harrison Catering Services Ltd. - Strategy, SWOT and Corporate Finance Report Summary Harrison Catering Services Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Aggreko Plc (AGK)-エネルギー分野:企業M&A・提携分析
    Summary Aggreko plc (Aggreko) is a provider of power generation and industrial heating and cooling solutions. It produces power; installs and operates modular and mobile power plants; and develops and rents electric solutions and equipment. The company offers range of diesel and gas power generators …
  • Magnolia Petroleum Plc (MAGP):企業の財務・戦略的SWOT分析
    Summary Magnolia Petroleum Plc (Magnolia Petroleum) is an oil and gas company. The company explores, acquires, and develops oil and natural gas properties. It holds interests in producing properties in two project areas such as Bakken shale in North Dakota and the proven Mississippi Lime, Woodford a …
  • Cristal Therapeutics BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Cristal Therapeutics BV (Cristal Therapeutics) is a pharmaceutical company that develops nano-medicines for the treatment of cancer and chronic inflammatory disorders. The company develops CriPec docetaxel, a lead product candidate for solid tumours. It also provides peptide-based products, …
  • G4S plc:企業の戦略・SWOT・財務情報
    G4S plc - Strategy, SWOT and Corporate Finance Report Summary G4S plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Culture Landmark Investment Ltd:企業の戦略・SWOT・財務分析
    Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report Summary Culture Landmark Investment Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Nippon Paper Industries Co., Ltd.:企業の戦略・SWOT・財務情報
    Nippon Paper Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Paper Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Valener Inc (VNR):石油・ガス:M&Aディール及び事業提携情報
    Summary Valener Inc (Valener) is an investment holding company that focuses on the energy sector. Through its investments in energy portfolio, the company offers storage, distribution, transportation and allied energy services. The company has interest in Gaz Metro and is its limited partner. Gaz Me …
  • Pluristem Therapeutics Inc (PSTI):企業の財務・戦略的SWOT分析
    Summary Pluristem Therapeutics Inc (Pluristem) operates as a clinical-stage biotherapy company that focuses on the development of placental-derived cell therapies. Its PLacental eXpanded (PLX) cells are adherent stromal cells that can be administered to patients without tissue or genetic matching. T …
  • TRACON Pharmaceuticals Inc (TCON):医療機器:M&Aディール及び事業提携情報
    Summary TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TRC253, TRC694, and TRC205. Its lead product …
  • Grant Thornton International Ltd:企業の戦略的SWOT分析
    Grant Thornton International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Old Dominion Freight Line, Inc. (ODFL):企業の財務・戦略的SWOT分析
    Old Dominion Freight Line, Inc. (ODFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • William Hill PLC:企業の戦略・SWOT・財務分析
    William Hill PLC - Strategy, SWOT and Corporate Finance Report Summary William Hill PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Synthos SA:企業の戦略的SWOT分析
    Synthos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Hydrodec Group plc (HYR):企業の財務・戦略的SWOT分析
    Summary Hydrodec Group Plc (Hydrodec) is an oil and gas company that offers oil refining services. The company produces, markets and distributes transformer oil and naphthenic base oil. It undertakes collection, transportation and processing of used non-PCB and PCB-contaminated naphthenic-based tran …
  • Laboratorios Farmaceuticos Rovi SA (ROVI):企業の財務・戦略的SWOT分析
    Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription and hospital products. The company's product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovas …
  • Cleanaway Waste Management Ltd (CWY):企業の財務・戦略的SWOT分析
    Cleanaway Waste Management Ltd (CWY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆